Source: BIOVIA Blog

BIOVIA Blog Designing a New TB Vaccine Using Software Assisted Antigen Comparison

Tuberculosis is a disease that most immunologists and cellular biologists will be familiar with. As a bacterium, m. tuberculosis is notable for its ability to take root in human hosts for long periods of time, exhibiting extreme genetic variability, drug resistance, stealth and ultimately lethality.1 Because of this, TB is [...]The post Designing a New TB Vaccine Using Software Assisted Antigen Comparison appeared first on Blog.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Leif Pedersen's photo - CEO of Biovia

CEO

Leif Pedersen

CEO Approval Rating

87/100